Personalized Medicine in Severe Asthma:
Applying Emerging Data and Treatments to Everyday Clinical Practice

Provided by National Jewish Health.

These educational activities are supported by educational grants from AstraZeneca Pharmaceuticals LP, GlaxoSmithKline, and Sanofi Genzyme and Regeneron Pharmaceuticals.

Specialty: Pulmonologists, Allergists, Primary Care, Internal Medicine

Topic: Severe Asthma

Target Audience: These activities are intended for allergists, pulmonologists, primary care physicians, and pediatricians. Physician assistants, advanced practice nurses and other health care providers involved in the treatment of patients with severe asthma will also be targeted for this activity in support of multidisciplinary learning.

Program Overview: Severe asthma is a leading cause of asthma-related morbidity and mortality. Individuals with severe asthma face excess costs and quality of life constraints far more than those with other manifestations of the disease. In this course, you will learn about the latest evidence-based treatments for severe asthma in addition to a review of established therapies that are essential in helping patients achieve optimal functional status and quality of life. This course will address how you can help patients with severe asthma better understand the importance of using medications properly and consistently.


Module 1 – Pathophysiology


Module 2 – Current and Emerging Asthma Therapies


Module 3 – Roundtable Discussion on Personalized Treatment Approaches